TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8783218

Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction of the left visual field
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction of the right visual field
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Hypnotic obstruction
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Right visual field left hemisphere P200 reduction
Number of subjects: 22
Study: 1740583

Group type: EXPERIMENTAL
Intervention: Honeybee venom immunotherapy (VIT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Yellow jacket venom immunotherapy (VIT)
Number of subjects: 205
Study: 6326999

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy (4200 rad)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Combined radiotherapy and chemotherapy (3000 rad)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined radiotherapy and chemotherapy
Number of subjects: 101
Study: 31902373

Group type: EXPERIMENTAL
Intervention: Whole raw Gala apples (approximately 200 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (without apples)
Number of subjects: 26
Study: 31150780

Group type: EXPERIMENTAL
Intervention: Placebo conditioning with instrumental control over treatment administration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard passive placebo conditioning without any control over treatment administration
Number of subjects: 87

Group type: COMPARATOR
Intervention: Natural history control group with no conditioning
Number of subjects: 87
Study: 29340524

Group type: EXPERIMENTAL
Intervention: FFC group (400 µs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SSP group (50 µs pulse)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: MSP group (100 µs pulse)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: SP group (300 µs pulse)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Positive control group (no treatment)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Negative control group (12 teeth without carious lesion)
Number of subjects: 72
Study: 27111078

Group type: EXPERIMENTAL
Intervention: Ipsilateral nonvascularized autograft and periosteal repair
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (other limb-salvage or amputation procedures)
Number of subjects: 4
Study: 24673044

Group type: EXPERIMENTAL
Intervention: Auricular points group (magnetic-ball sticking therapy)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 90
Study: 22337561

Group type: EXPERIMENTAL
Intervention: Levetiracetam 3000 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 20590745

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 4555
Study: 16633709

Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field (PEMF) therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham PEMF
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corticosteroid + anesthetic agent injection
Number of subjects: 60
Study: 16257793

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 331

Group type: COMPARATOR
Intervention: Control group of a randomised trial of epoetin alfa
Number of subjects: 331
Study: 11879235

Group type: EXPERIMENTAL
Intervention: epoetin omega
Number of subjects: 38

Group type: COMPARATOR
Intervention: epoetin alfa
Number of subjects: 38
Study: 10397617

Group type: EXPERIMENTAL
Intervention: Fast dissolving reference formulation
Number of subjects: 480

Group type: COMPARATOR
Intervention: Hypothetical slow dissolving test formulation
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Cmax/AUCt measure
Number of subjects: 480
Study: 9097709

Group type: EXPERIMENTAL
Intervention: p53 staining
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PCNA staining
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ki67 staining
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Higher staining scores for p53, PCNA, and Ki67
Number of subjects: 120
Study: 1915135

Group type: EXPERIMENTAL
Intervention: Diazemuls
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional diazepam
Number of subjects: 26
Study: 6353428

Group type: EXPERIMENTAL
Intervention: Oxymetazoline (0.025%) ophthalmic solution
Number of subjects: 38

Group type: COMPARATOR
Intervention: Naphazoline (0.04%) solution
Number of subjects: 38
Study: 31469749

Group type: EXPERIMENTAL
Intervention: Fractional ablative CO2 laser treatment
Number of subjects: 29
Study: 29665830

Group type: EXPERIMENTAL
Intervention: Conventional therapy plus a brief GOH-based intervention (CT-GOHT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy (CT)
Number of subjects: 40
Study: 29044223

Group type: EXPERIMENTAL
Intervention: Bilateral transcranial direct current stimulation (tDCS) over sensorimotor areas
Number of subjects: 26
Study: 26199142

Group type: EXPERIMENTAL
Intervention: Telehealth remote monitoring with paired glucose testing and asynchronous virtual visits
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Telehealth remote monitoring
Number of subjects: 90
Study: 23900369

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 121
Study: 19949848

Group type: EXPERIMENTAL
Intervention: Housing Opportunities for People with AIDS (HOPWA) rental assistance
Number of subjects: 630

Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 630
Study: 18262140

Group type: EXPERIMENTAL
Intervention: Transdermal Scopolamine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 16606646

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) 2 g/day
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 15005736

Group type: EXPERIMENTAL
Intervention: Specific allergy vaccination (SAV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11153633

Group type: EXPERIMENTAL
Intervention: Hypothermic group (n = 15), cooled to 32 to 33 degrees C after administration of vecuronium, midazolam, and buprenorphine.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normothermic group (n = 11), body temperature controlled at 36 to 37 degrees C with the same treatment as hypothermic group.
Number of subjects: 26
Study: 9100038

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 to 600 mg/d plus prednisone 2.5 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 8103146

Group type: EXPERIMENTAL
Intervention: Physicians' preferences for withdrawing life support
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Physicians' decision-making biases
Number of subjects: 862
Study: 2994436

Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 85
Study: 3219853

Group type: EXPERIMENTAL
Intervention: TCu 380Ag
Number of subjects: 884

Group type: COMPARATOR
Intervention: Multiload Cu 375
Number of subjects: 884
Study: 28724338

Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT (iCBT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 140
Study: 27476798

Group type: EXPERIMENTAL
Intervention: Emergency Department (ED) care
Number of subjects: 1150

Group type: COMPARATOR
Intervention: General Practitioner (GP) care
Number of subjects: 1150
Study: 23900984

Group type: EXPERIMENTAL
Intervention: Intravenous propofol using intermittent bolus technique
Number of subjects: 702

Group type: COMPARATOR
Intervention: Intravenous propofol using continuous infusion
Number of subjects: 702
Study: 24336997

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT) program
Number of subjects: 0
Study: 21050553

Group type: EXPERIMENTAL
Intervention: Combination of dinoprostone suppository and ethacridine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Ethacridine alone
Number of subjects: 96
Study: 18437172

Group type: EXPERIMENTAL
Intervention: Various compounds targeting MAPK pathway
Number of subjects: 0
Study: 16628069

Group type: EXPERIMENTAL
Intervention: MgSO4 80 mmol/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 60
Study: 15518608

Group type: COMPARATOR
Intervention: Pravastatin alone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Simvastatin with verapamil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atorvastatin with mibefradil
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atorvastatin with itraconazole
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All 3 statins with clarithromycin
Number of subjects: 3
Study: 10863176

Group type: EXPERIMENTAL
Intervention: Low grade vulvar intraepithelial neoplasia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Low grade vaginal intraepithelial neoplasia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Low grade penile intraepithelial neoplasia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: High grade intraepithelial neoplasia
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Invasive vulvar carcinoma
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Invasive vaginal carcinoma
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Invasive penile carcinoma
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Overall intraepithelial neoplasias
Number of subjects: 423
Study: 9504888

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8354918

Group type: EXPERIMENTAL
Intervention: ranitidine plus amoxicillin plus metronidazole
Number of subjects: 104

Group type: COMPARATOR
Intervention: ranitidine plus placebo
Number of subjects: 104
Study: 3490195

Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg IV for induction; 7 +/- 2 mg/min continuous infusion for maintenance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methohexital, 1.5 mg/kg IV for induction; 6 +/- 2 mg/min continuous infusion for maintenance
Number of subjects: 60
Study: 30889524

Group type: EXPERIMENTAL
Intervention: Pictorial HWLs
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: 50% HWLs
Number of subjects: 992

Group type: COMPARATOR
Intervention: No-HWL Control
Number of subjects: 992

Group type: EXPERIMENTAL
Intervention: 30% HWLs
Number of subjects: 992
Study: 28906205

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate and cilostazol (combined)
Number of subjects: 60
Study: 27197106

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback treatment after progressive muscular relaxation training
Number of subjects: 12

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 12
Study: 24569437

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (15-35 years)
Number of subjects: 13388

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (≥ 35 years)
Number of subjects: 13388

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption (>0-1 drink/day)
Number of subjects: 13388

Group type: COMPARATOR
Intervention: Low physical activity
Number of subjects: 13388
Study: 22854660

Group type: EXPERIMENTAL
Intervention: Quinvaxem (®) vaccine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Booster dose of Quinvaxem (®)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Quinvaxem (®) with concomitant measles vaccine
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Quinvaxem (®)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Three production lots of Quinvaxem (®)
Number of subjects: 360
Study: 20488469

Group type: COMPARATOR
Intervention: Low dose antibiotic prophylaxis
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Endoscopic therapy (dextranomer/hyaluronic acid copolymer)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Surveillance group on antibiotic treatment only for febrile urinary tract infection
Number of subjects: 203
Study: 18564730

Group type: EXPERIMENTAL
Intervention: Bovine-derived hydroxyapatite combined with Cissus quadrangularis (CQ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Bovine-derived hydroxyapatite alone
Number of subjects: 20
Study: 16048456

Group type: EXPERIMENTAL
Intervention: AQ‐J (Autism Spectrum Quotient - Japanese version)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AQ‐J-21 (21 items associated with HPDD diagnosis)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: AQ‐J-10 (10 items with effect size > 0.17)
Number of subjects: 240

Group type: COMPARATOR
Intervention: AQ‐J
Number of subjects: 240
Study: 12436050

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 11227394

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 692

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 692
Study: 9179553

Group type: COMPARATOR
Intervention: Yoga (6 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aerobic training (6 weeks)
Number of subjects: 26
Study: 8097280

Group type: EXPERIMENTAL
Intervention: EMD 49980 monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EMD 49980 co-administered with levodopa
Number of subjects: 0
Study: 2950359

Group type: EXPERIMENTAL
Intervention: VAC/FMC chemotherapy with bromoergocryptine
Number of subjects: 86

Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy without bromoergocryptine
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: VAC/FMC chemotherapy with medroxyprogesterone acetate (MAP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: VAC/FMC chemotherapy without MAP
Number of subjects: 86
Study: 31314693

Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard Supportive Care (SSC)
Number of subjects: 262
Study: 31486272

Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27393139

Group type: EXPERIMENTAL
Intervention: Lithium carbonate 25 mg/kg TBW/day in two daily doses
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 61
Study: 25965624

Group type: EXPERIMENTAL
Intervention: Creatinine
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: NGAL
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: KIM-1
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: CysC
Number of subjects: 190
Study: 23117500

Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 0-7 days)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 8-14 days)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: 15-30 days)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: HIV testing and counseling (timing of first testing: >30 days)
Number of subjects: 508
Study: 21639864

Group type: EXPERIMENTAL
Intervention: Age‐related, height‐based (ARHB)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Direct distance nose‐ear‐mid‐umbilicus (NEMU)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Direct distance nose‐ear‐xiphoid (NEX)
Number of subjects: 173
Study: 19931755

Group type: EXPERIMENTAL
Intervention: MAR Method (using a fist to cover a surface area of blood)
Number of subjects: 74
Study: 16766279

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT) and 5 mg amyloride
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50 mg hydrochlorothiazide (HCT) and 50 mg spironolactone
Number of subjects: 28

Group type: COMPARATOR
Intervention: HCT-spironolactone vs HCT and HCT-amyloride
Number of subjects: 28
Study: 15233245

Group type: EXPERIMENTAL
Intervention: Supervised outpatient exercise training program (3 times weekly on non-dialysis days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Training program with stationary bicycles during HD sessions (3 times weekly)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 48
Study: 11079993

Group type: EXPERIMENTAL
Intervention: Health information with a medical award present on the page
Number of subjects: 137

Group type: COMPARATOR
Intervention: Health information without a medical award present on the page
Number of subjects: 137
Study: 9134070

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus four smoking cessation sessions with a nurse-practitioner (moderate-intensity condition, MI)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Nicotine patch plus four smoking cessation sessions plus 16 weekly individual cognitive/behavioral relapse-prevention therapy sessions (high-intensity condition, HI)
Number of subjects: 69
Study: 7955243

Group type: EXPERIMENTAL
Intervention: Right gastroepiploic artery (GEA)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Inferior epigastric artery (IEA)
Number of subjects: 290
Study: 3310727

Group type: EXPERIMENTAL
Intervention: Nalbuphine (NAL) 1.5 mg/kg BW
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nalbuphine (NAL) 2.5 mg/kg BW
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fentanyl (FE) 0.005 mg/kg BW
Number of subjects: 20
Study: 29344405

Group type: EXPERIMENTAL
Intervention: LSVT LOUD® (16 sessions over 4 weeks)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: SLT (individualised content, typically weekly sessions for 6-8 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 89
Study: 28253897

Group type: COMPARATOR
Intervention: Complex intervention delivered over 12 months to promote recruitment.
Number of subjects: 72
Study: 26582115

Group type: EXPERIMENTAL
Intervention: Educational video program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Verbal education with explanatory note (Control)
Number of subjects: 101
Study: 23254770

Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 77
Study: 21681652

Group type: EXPERIMENTAL
Intervention: MOXI‐AF (0.5% moxifloxacin ophthalmic solution) dosed twice-daily for 3 days
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: MOXI‐AF (0.5% moxifloxacin ophthalmic solution)
Number of subjects: 1180
Study: 18778380

Group type: EXPERIMENTAL
Intervention: Web-based tutorial
Number of subjects: 21

Group type: COMPARATOR
Intervention: Didactic group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Web-based group
Number of subjects: 21
Study: 17175636

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 ml of 50 g/L fructose daily for 3 days after escharectomy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous infusion of glucose 1 day after escharectomy for 3 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 500 ml of 50 g/L fructose
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intravenous infusion of glucose
Number of subjects: 41
Study: 12585341

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 20 mg daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 8
Study: 10945089

Group type: EXPERIMENTAL
Intervention: HoNOSCA (Health of the Nation Outcome Scales for Children and Adolescents)
Number of subjects: 203
Study: 9179087

Group type: EXPERIMENTAL
Intervention: Lisinopril (18 ± 1 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7866044

Group type: EXPERIMENTAL
Intervention: Amodiaquine (30 mg/kg for 3 days)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Chloroquine (30 mg/kg for 3 days)
Number of subjects: 100
Study: 2475722

Group type: EXPERIMENTAL
Intervention: Cifenline (130 mg or 160 mg twice daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 176876

Group type: EXPERIMENTAL
Intervention: Cholestyramine (12, 16, or 20 g daily)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neomycin (1, 1.5, or 2 g daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (none specified)
Number of subjects: 35
Study: 30535356

Group type: EXPERIMENTAL
Intervention: Prototype-based workflow
Number of subjects: 18

Group type: COMPARATOR
Intervention: Common computational approach
Number of subjects: 18
Study: 29035887

Group type: EXPERIMENTAL
Intervention: 900 mg of Valeriana officinalis extract (valerenic acid 0.8%)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (an equal dose of vitamin E)
Number of subjects: 15
Study: 26409920

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 0.5% ropivacaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wound infiltration with 0.5% ropivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Wound infiltration
Number of subjects: 70
Study: 24607293

Group type: EXPERIMENTAL
Intervention: melatonin 3 mg/day
Number of subjects: 48

Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 48
Study: 22782199

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole, 480 mg, once daily
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 109 colony-forming units, twice daily
Number of subjects: 252
Study: 19254330

Group type: EXPERIMENTAL
Intervention: Differential index (HRV measurement)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Time and frequency indices of HRV (SDNN, r-MSSD, SDNNIDX, total power, VLF, LF, HF)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: pNN50 and LF/HF
Number of subjects: 261

Group type: COMPARATOR
Intervention: SDNN, SDNNIDX, total power, LF, LF/HF
Number of subjects: 261

Group type: COMPARATOR
Intervention: Differential index, pNN50, HF
Number of subjects: 261